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Introduction {#jah31750-sec-0004}
============

Chronic kidney disease is a costly disease, and the costs associated with the care of patients with end‐stage renal disease are estimated to exceed US\$1 trillion globally.[1](#jah31750-bib-0001){ref-type="ref"} Albuminuria or microalbuminuria, albumin excretion rate ≥30 mg/24 hours or albumin/creatinine ratio (ACR) ≥30 mg/g (≥3 mg/mmol), is used as a marker of renal damage and is used to define chronic kidney disease along with low estimated glomerular filtration rate (eGFR).[2](#jah31750-bib-0002){ref-type="ref"} Albuminuria is not only a predictor of development and progression of diabetic[3](#jah31750-bib-0003){ref-type="ref"} and nondiabetic[4](#jah31750-bib-0004){ref-type="ref"} renal diseases, but is a marker of endothelial dysfunction.[5](#jah31750-bib-0005){ref-type="ref"} In 1969, Keen and colleagues first showed that increased urinary albumin excretion (microalbuminuria) occurred in people with type 2 diabetes mellitus compared with controls during an oral glucose tolerance test.[6](#jah31750-bib-0006){ref-type="ref"}

A recent meta‐analysis based on more than 100 000 individuals with ACR data and 1.1 million participants with dipstick data from 21 general population cohorts demonstrated that albuminuria was associated with all‐cause and cardiovascular mortality independently of each other and traditional cardiovascular risk factors.[7](#jah31750-bib-0007){ref-type="ref"} These data from 21 studies from 14 countries of Asia, Europe, North America, and Oceania showed consistency in both continuous and categorical models for ACR across the different regional cohorts.

Both cardiovascular disease (CVD) and diabetes mellitus share many risk factors in common (the "common soil" hypothesis[8](#jah31750-bib-0008){ref-type="ref"}), but whether urine albumin:creatinine ratio (UACR) below 30 mg/g similarly predicts mortality outcomes, hypertension, and diabetes mellitus in the same population is uncertain. It is well established that microalbuminuria is associated with all‐cause and cardiovascular mortality, and microalbuminuria is associated with diabetes mellitus[9](#jah31750-bib-0009){ref-type="ref"} and resistant hypertension.[10](#jah31750-bib-0010){ref-type="ref"} However, although it has been shown that urinary albumin excretion predicts blood pressure progression in people without diabetes mellitus or hypertension, at levels of UACR below 30 mg/g,[9](#jah31750-bib-0009){ref-type="ref"} it is less certain whether these levels are associated with CVD mortality, and increased risk of incident hypertension and incident diabetes mellitus.

The aim of the study was to test the hypothesis that UACR below 30 mg/g was associated with the following outcomes: incident hypertension, incident diabetes mellitus, and all‐cause and CVD mortality during a maximum of 11 years of follow‐up, in a middle‐aged relatively healthy occupational cohort with exclusion of those with UACR \>30 mg/g.

Methods {#jah31750-sec-0005}
=======

Study Population {#jah31750-sec-0006}
----------------

The study population consisted of individuals who participated in a comprehensive health screening program with UACR at Kangbuk Samsung Hospital, Seoul, Korea from 2002 to 2012 (N=44 964). The purpose of the screening program was to promote health through early detection of chronic diseases and their risk factors. Additionally, the Korean Industrial Safety and Health Law demands that working individuals participate in an annual or biennial health examination. Participants, who were employees or spouses of companies or local governmental organizations, registered individually for the program. For this analysis, we opportunistically investigated associations between low levels of albuminuria (below the threshold for defining microalbuminuria), and risks of incident hypertension, incident diabetes mellitus, and CVD mortality at follow‐up. Incident hypertension was defined by the presence of new antihypertensive medication, self‐reporting by the patient of hypertension, and a blood pressure at follow‐up ≥140/90 mm Hg; incident diabetes mellitus was defined by new antidiabetic medication, self‐reporting by the patient of diabetes mellitus, or a fasting glucose at follow‐up ≥126 mg/dL. Subjects were excluded for 1 or more of the following reasons: UACR ≥30 mg/g, subjects with missing data for smoking, alcohol, or exercise at baseline; subjects with a history of cancer; and subjects with unknown mortality status. The total number of eligible subjects for testing associations with all‐cause and CVD mortality was 37 091 (median follow‐up \[FU\]: 5.13 years and mean \[SD\] FU: 4.99 \[2.57\] years). To test the effect of low‐grade albuminuria for incident type 2 diabetes mellitus and hypertension, we studied 13 475 subjects who had baseline UACR and follow‐up data on more than 1 occasion between 2002 and 2013. To analyze associations between UACR and incident hypertension, we additionally excluded the following: subjects with missing data for smoking, alcohol, or exercise at baseline; and subjects with hypertension at baseline; thus, the total number of eligible subjects for this analysis was 9102 (median FU: 2.68 years and mean \[SD\] FU: 3.52 \[2.13\] years). For testing associations between UACR and incident diabetes mellitus, data were available on 10 930 subjects (median FU: 2.98 years and mean \[SD\] FU: 3.47 \[2.17\]) years after excluding subjects for missing data and subjects with type 2 diabetes mellitus at baseline.

This study was approved by the Institutional Review Board of Kangbuk Samsung Hospital. Requirement for informed consent was waived as de‐identified information was retrieved retrospectively.

Measurements {#jah31750-sec-0007}
------------

As part of the health screening program, individuals completed questionnaires related to their medical and social history and medication use. Individuals were asked about duration of education (years), frequency of exercise (none, less than once a week, at least once a week, ≥3 times per week \[regular exercise\]), smoking history (never, former, or current), and alcohol consumption (g/week).

Trained staff also collected anthropometric measurements and vital statistics. Body weight was measured in light clothing with no shoes to the nearest 0.1 kg using a digital scale. Height was measured to the nearest 0.1 cm. Body mass index was calculated as weight in kilograms divided by height in meters squared. Blood pressure was measured using standard mercury sphygmomanometers. Blood samples were collected after at least 10 hours of fasting and were analyzed in the same core clinical laboratory. The core clinical laboratory has been accredited and participates annually in inspections and surveys by the Korean Association of Quality Assurance for Clinical Laboratories.

Urinary albumin excretion was measured from an early‐morning urine sample as the UACR. The urinary albumin concentration was determined by immunoradiometry (radioimmunological competition assay; Immunotech) and immunoturbidimetric assay (Roche Modular P800), and urinary creatinine concentration was measured by a modified Jaffe method. The UACR measured in a spot urine sample is highly correlated with the 24‐hour urine albumin excretion.[11](#jah31750-bib-0011){ref-type="ref"} All subjects with a UACR ≥30 mg/g were excluded from these analyses.

Ascertainment of Mortality {#jah31750-sec-0008}
--------------------------

Deaths among participants were identified by matching the information to death records from the National Statistical Office using identification numbers assigned to subjects at birth. Causes of death were coded centrally by trained coders using the ICD‐10 classification (International Classification of Diseases, 10th revision) and ICD 00‐99 was considered to represent cardiovascular death.

Statistical Analyses {#jah31750-sec-0009}
--------------------

The statistical analysis was performed using STATA version 11.2 (StataCorp LP, College Station, TX). Reported *P*‐values were 2‐tailed, and \<0.05 were considered statistically significant. The distribution of continuous variables was evaluated and transformations were conducted for nonparametric variables. Cox proportional hazards models were used to estimate hazard ratios (HRs) and 95% CIs for mortality in each quartile, compared with the lowest quartile as reference for urine ACR. For testing linear risk trends, we used the quartile rank as a continuous variable in the regression models. We checked the proportional hazards assumption by examining graphs of estimated log (−log) survival. The models were initially adjusted for age, sex, center, year of screening examination, smoking status, alcohol intake, regular exercise, and education level (model 1). In Model 2, the models were further adjusted for body mass index, hypertension, diabetes mellitus, and history of CVD. Model 3 includes adjustment for the same factors as Model 2 plus adjustment for eGFR. Associations were examined between urine ACR quartiles and all‐cause and CVD mortality in clinically relevant subgroups.

For incident type 2 diabetes mellitus, models included adjustment for age, sex, center, year of screening examination, smoking status, alcohol intake, regular exercise, and education level (Model 1); Model 1 plus adjustment for fasting plasma glucose, family history of diabetes mellitus and body mass index (Model 2). Model 3 includes adjustment for the same factors as Model 2 plus adjustment for eGFR. For incident hypertension, Model 1 included adjustment for age, sex, center, year of screening examination, smoking status, alcohol intake, regular exercise, and education level (Model 1); Model 1 plus adjustment for systolic blood pressure and body mass index (Model 2). Model 3 includes adjustment for the same factors as Model 2 plus adjustment for eGFR. *P*\<0.05 was considered significant.

Results {#jah31750-sec-0010}
=======

The baseline characteristics of the cohort according to death, CVD death, incident hypertension, and incident diabetes mellitus at follow‐up are shown in Table [1](#jah31750-tbl-0001){ref-type="table-wrap"}. There were 349 deaths during follow‐up and blood pressure and the proportion of subjects with hypertension and diabetes mellitus was higher in subjects who died during follow‐up. UACR was increased at baseline in subjects who died during follow‐up. To investigate associations between increasing UACR and risk factors for all‐cause and cardiovascular mortality, we examined the trends across UACR quartiles and risk factors for all‐cause and cardiovascular mortality. Table [2](#jah31750-tbl-0002){ref-type="table-wrap"} shows the baseline characteristics of the cohort according to baseline UACR quartiles. Quartiles of UACR were for quartile 1: \<3.4 mg/g (0.38 mg/mmol); quartile 2: 3.4 to 4.7 mg/g (0.38--0.53 mg/mmol); quartile 3: 4.7 to 7.4 mg/g (0.53--0.84 mg/mmol), and for the highest quartile ≥7.4 mg/g (0.84 mg/mmol). There was a significant increase in the proportion of people with diabetes mellitus, obesity, and hypertension across UACR quartiles. There were remarkably similar eGFR values across UACR quartiles, with eGFR varying by only 0.4 mL/min across UACR quartiles.

###### 

Baseline Characteristics of the Cohort According to Vital and Disease Status at Follow‐Up

  Baseline Characteristics                                      Overall              No Death             New Death            *P‐*Value   No CVD Death         New CVD Death        *P‐*Value   No Incident Hypertension   Incident Hypertension   *P‐*Value   No Incident Diabetes Mellitus   Incident Diabetes Mellitus   *P‐*Value
  ------------------------------------------------------------- -------------------- -------------------- -------------------- ----------- -------------------- -------------------- ----------- -------------------------- ----------------------- ----------- ------------------------------- ---------------------------- -----------
  Total number                                                  37 091               37 091               37 091                           37 091               37 091                           9102                       9102                                10 930                          10 930                       
  Number of event                                               37 091               36 742               349                              37 041               50                               8139                       963                                 10 419                          511                          
  N (%) Men                                                     19 688 (53.1)        19 437 (52.9)        251 (71.9)                       19 652 (53.1)        36 (72.0)                        4187 (51.4)                665 (69.1)                          5768 (55.4)                     360 (70.5)                   
  Age, y                                                        45.8 (11.9)          45.7 (11.9)          57.2 (12.0)          \<0.001     45.8 (11.9)          58.9 (12.6)          \<0.001     42.1 (10.1)                47.6 (10.2)             \<0.001     43.7 (10.6)                     49.6 (9.6)                   \<0.001
  BMI, kg/m^2^                                                  23.6 (3.2)           23.6 (3.2)           23.9 (3.3)           0.109       23.6 (3.2)           24.0 (3.6)           0.402       23.0 (2.9)                 24.6 (2.9)              \<0.001     23.4 (3.0)                      25.3 (2.8)                   \<0.001
  Systolic BP, mm Hg                                            115.9 (14.9)         115.9 (14.8)         123.6 (16.8)         \<0.001     115.9 (14.8)         127.4 (18.8)         \<0.001     110.4 (10.8)               119.1 (9.9)             \<0.001     114.7 (14.0)                    121.8 (14.4)                 \<0.001
  Diastolic BP, mm Hg                                           74.9 (9.9)           74.9 (9.9)           78.5 (9.8)           \<0.001     74.9 (9.9)           81.2 (10.7)          \<0.001     71.6 (7.8)                 77.5 (6.7)              \<0.001     74.5 (9.7)                      79.2 (9.4)                   \<0.001
  Higher education (%)[a](#jah31750-note-0002){ref-type="fn"}   11 046 (55.7)        10 964 (56.0)        82 (35.2)            \<0.001     11 034 (55.8)        12 (35.3)            0.016       2927 (70.4)                316 (55.2)              \<0.001     3710 (67.3)                     134 (47.9)                   \<0.001
  Regular exercise (%)[b](#jah31750-note-0003){ref-type="fn"}   7183 (19.4)          7122 (19.4)          61 (17.5)            0.370       7177 (19.4)          6 (12.0)             0.187       1475 (18.1)                213 (22.1)              0.003       1988 (19.1)                     114 (22.3)                   0.071
  Current smoker (%)                                            9774 (26.4)          9654 (26.3)          120 (34.4)           0.001       9758 (26.3)          16 (32.0)            0.364       2111 (25.9)                289 (30.0)              0.007       2674 (25.7)                     163 (31.9)                   0.002
  Alcohol intake ≥20 g/day (%)                                  7542 (20.3)          7457 (20.3)          85 (24.4)            0.061       7533 (20.3)          9 (18.0)             0.682       1459 (17.9)                272 (28.3)              \<0.001     2076 (19.9)                     170 (33.3)                   \<0.001
  Fatty liver (%)                                               10 882 (29.3)        10 784 (29.4)        98 (28.1)            0.603       10 865 (29.3)        17 (34.0)            0.469       1960 (24.1)                378 (39.3)              \<0.001     2809 (27.0)                     299 (58.5)                   \<0.001
  Obesity (%)                                                   11 691 (31.5)        11 569 (31.5)        122 (35.0)           0.165       11 674 (31.5)        17 (34.0)            0.706       1976 (24.3)                407 (42.3)              \<0.001     3064 (29.4)                     271 (53.0)                   \<0.001
  Hypertension (%)                                              8740 (23.6)          8594 (23.5)          146 (41.8)           \<0.001     8714 (23.6)          26 (52.0)            \<0.001                                                                    ---                             ---                          ---
  Diabetes mellitus (%)                                         2314 (6.2)           2254 (6.1)           60 (17.2)            \<0.001     2305 (6.2)           9 (18.0)             0.001       ---                        ---                     ---         1323 (12.7)                     1443 (23.5)                  \<0.001
  Hx of CVD (%)                                                 3016 (8.1)           2978 (8.1)           38 (10.9)            0.058       37 041 (8.1)         9 (18.0)             0.011       ---                        ---                     ---         ---                             ---                          ---
  Insulin, μIU/mL                                               8.01 (6.27--10.26)   8.01 (6.27--10.26)   8.23 (6.63--10.68)   0.001       8.01 (6.27--10.26)   8.32 (6.58--10.36)   0.411       4.69 (3.1--6.73)           5.5 (4.01--8.03)        0.002       4.8 (3.17--6.85)                6.15 (4.1--8.71)             0.007
  Glucose, mg/dL                                                96.4 (17.8)          96.3 (17.7)          104.0 (27.3)         \<0.001     96.4 (17.8)          101.8 (22.6)         0.033       93.4 (13.6)                99.1 (18.6)             \<0.001     92.6 (8.7)                      105.5 (10.9)                 \<0.001
  Total cholesterol, mg/dL                                      195.9 (35.2)         195.9 (35.2)         193.5 (37.9)         0.202       195.9 (35.2)         200.2 (26.7)         0.383       193.2 (33.7)               202.1 (35.2)            \<0.001     195.2 (34.1)                    207.3 (35.7)                 \<0.001
  LDL‐C, mg/dL                                                  115.6 (31.3)         115.6 (31.3)         111.0 (32.0)         0.006       115.6 (31.3)         119.5 (22.9)         0.380       113.2 (30.0)               120.5 (31.7)            \<0.001     114.8 (30.4)                    122.7 (32.8)                 \<0.001
  HDL‐C, mg/dL                                                  55.7 (13.3)          55.7 (13.3)          55.0 (13.7)          0.317       55.7 (13.3)          55.2 (11.0)          0.767       56.9 (13.7)                54.2 (11.9)             \<0.001     56.5 (13.4)                     51.8 (11.0)                  \<0.001
  Triglycerides, mg/dL                                          103 (72--154)        103 (72--154)        114 (82--162)        \<0.001     103 (72--154)        117 (82--167)        0.215       94 (67--140)               122 (86--177)           \<0.001     100 (70--148)                   152 (104--218)               \<0.001
  HOMA IR                                                       1.87 (1.40--2.48)    1.86 (1.40--2.48)    2.05 (1.55--2.69)    \<0.001     1.86 (1.40--2.48)    2.05 (1.60--2.48)    0.175       1.81 (1.36--2.34)          2.04 (1.60--2.70)       \<0.001     1.84 (1.40--2.37)               2.42 (1.88--3.17)            \<0.001
  eGFR, mL/min                                                  81.6 (14.4)          81.7 (14.4)          76.6 (13.0)          \<0.001     81.6 (14.4)          72.9 (12.9)          \<0.001     83.5 (14.4)                78.5 (12.0)             \<0.001     82.1 (14.2)                     77.5 (12.9)                  \<0.001

SI conversion factors (multiply the conversion factor to obtain SI unit): insulin, 6.945 (pmol/L); glucose, 0.0555 (mmol/L); total cholesterol, 0.0259 (mmol/L); LDL‐C, 0.0259 (mmol/L); HDL‐C, 0.0259 (mmol/L); triglycerides, 0.0113 (mmol/L). BMI indicates body mass index; BP, blood pressure; CVD, cardiovascular disease; eGFR, estimated glomerular filtration rate; HDL‐C, high‐density lipoprotein cholesterol; HOMA IR, homeostatic model assessment‐insulin resistance; LDL‐C, low‐density lipoprotein cholesterol.

≥College graduate.

≥3 times per week.

###### 

Baseline Characteristics of Study Subjects by UACR Quartile

  Characteristics                                               Overall              ACR Quartiles       *P* for Trend                                                
  ------------------------------------------------------------- -------------------- ------------------- ------------------- ------------------- -------------------- ---------
  N=37 091                                                                           9273                9274                9272                9272                 
  Age, y                                                        45.8 (11.9)          42.6 (10.7)         44.5 (11.3)         46.6 (11.9)         49.5 (12.5)          \<0.001
  BMI, kg/m^2^                                                  23.6 (3.2)           23.7 (2.9)          23.3 (3.0)          23.4 (3.2)          24.0 (3.5)           \<0.001
  Systolic BP, mm Hg                                            115.9 (14.9)         113.5 (12.5)        113.7 (13.7)        115.8 (14.8)        120.7 (16.9)         \<0.001
  Diastolic BP, mm Hg                                           74.9 (9.9)           73.8 (9.0)          73.7 (9.5)          74.8 (9.9)          77.5 (10.7)          \<0.001
  Higher education (%)[a](#jah31750-note-0005){ref-type="fn"}   11 046 (55.7)        3138 (68.3)         2893 (58.9)         2651 (52.7)         2364 (44.8)          \<0.001
  Regular exercise (%)[b](#jah31750-note-0006){ref-type="fn"}   7183 (19.4)          1796 (19.4)         1798 (19.4)         1799 (19.4)         1790 (19.3)          0.925
  Current smoker (%)                                            9774 (26.4)          3566 (38.5)         2448 (26.4)         1914 (20.6)         1846 (19.9)          \<0.001
  Alcohol intake ≥20 g/day (%)                                  7542 (20.3)          2447 (26.4)         1865 (20.1)         1535 (16.6)         1695 (18.3)          \<0.001
  Obesity (%)                                                   11 691 (31.5)        2881 (31.1)         2611 (28.2)         2732 (29.5)         3467 (37.4)          \<0.001
  Hypertension (%)                                              8740 (23.6)          1363 (14.8)         1708 (18.5)         2180 (23.6)         3489 (37.7)          \<0.001
  Diabetes mellitus (%)                                         2314 (6.2)           246 (2.7)           378 (4.08)          551 (5.9)           1139 (12.3)          \<0.001
  Hx of CVD (%)                                                 3016 (8.1)           593 (6.4)           732 (7.9)           810 (8.7)           881 (9.5)            \<0.001
  Insulin, μIU/mL                                               8.01 (6.27--10.26)   7.69 (5.8--9.83)    8.0 (6.36--10.09)   8.1 (6.4--10.34)    8.29 (6.47--10.84)   \<0.001
  Glucose, mg/dL                                                96.4 (17.8)          93.9 (11.6)         94.4 (14.6)         96.0 (16.8)         101.2 (24.6)         \<0.001
  Total cholesterol, mg/dL                                      195.9 (35.2)         193.6 (33.5)        194.1 (34.2)        196.2 (35.4)        199.8 (37.3)         \<0.001
  LDL‐C, mg/dL                                                  115.6 (31.3)         116.0 (30.1)        114.2 (30.6)        114.8 (31.3)        117.5 (33.0)         0.001
  HDL‐C, mg/dL                                                  55.7 (13.3)          54.3 (12.8)         56.2 (13.3)         56.8 (13.7)         55.6 (13.4)          \<0.001
  Triglycerides, mg/dL                                          103 (72--154)        105 (75--152)       99 (70--146)        99 (69--149)        111 (76--169)        \<0.001
  HOMA IR                                                       1.87 (1.40--2.48)    1.75 (1.29--2.31)   1.84 (1.40--2.40)   1.88 (1.43--2.49)   2.01 (1.48--2.74)    \<0.001
  eGFR, mL/min                                                  81.6 (14.4)          81.7 (13.4)         81.6 (14.1)         81.8 (14.6)         81.4 (15.5)          0.309

SI conversion factors (multiply the conversion factor to obtain SI unit): insulin, 6.945 (pmol/L); glucose, 0.0555 (mmol/L); total cholesterol, 0.0259 (mmol/L); LDL‐C, 0.0259 (mmol/L); HDL‐C, 0.0259 (mmol/L); triglycerides, 0.0113 (mmol/L). BMI indicates body mass index; BP, blood pressure; CVD, cardiovascular disease; eGFR, estimated glomerular filtration rate; HDL‐C, high‐density lipoprotein cholesterol; HOMA IR, homeostatic model assessment‐insulin resistance; Hx, history; LDL‐C, low‐density lipoprotein cholesterol; UACR, urine albumin:creatinine ratio.

≥College graduate.

≥3 times per week.

We investigated associations between baseline UACR quartiles and all‐cause and CVD mortality. Table [3](#jah31750-tbl-0003){ref-type="table-wrap"} shows the HRs for the associations between UACR quartiles and all‐cause and CVD mortality. The fully adjusted models showed a significant trend with increasing UACR quartiles and CVD mortality. Adjustment for eGFR in these models had an impact on the strength of the association between UACR and all‐cause mortality. Before adjustment for eGFR, there was a significant trend for the association between UACR and all‐cause mortality, *P*=0.036, whereas after adjustment for eGFR, there was a decrease in the strength of the association between UACR and all‐cause mortality, *P*=0.078.

###### 

Risk of All‐Cause and CVD Mortality According to Baseline UACR Quartiles

  ACR Quartiles, mg/g   Person‐Years   Number of Events   Mortality Rate (100 000 Person‐Year)   Age‐Sex Adjusted HR (95% CI)   Multivariate HR[a](#jah31750-note-0008){ref-type="fn"}(95% CI)                                             
  --------------------- -------------- ------------------ -------------------------------------- ------------------------------ ---------------------------------------------------------------- -------------------- -------------------- --------------------
  All‐cause mortality                                                                                                                                                                                                                      
  Q1 (\<3.4 mg/g)       42 971.8       63                 146.6                                  1.00 (reference)               1.00 (reference)                                                 1.00 (reference)     1.00 (reference)     1.00 (reference)
  Q2 (3.4--4.7 mg/g)    47 491.7       67                 141.1                                  0.93 (0.66--1.32)              0.77 (0.49--1.20)                                                0.76 (0.49--1.18)    0.74 (0.48--1.15)    0.74 (0.47--1.15)
  Q3 (4.7--7.4 mg/g)    47 411.1       89                 187.7                                  1.13 (0.81--1.57)              1.05 (0.69--1.58)                                                1.04 (0.69--1.56)    0.99 (0.66--1.50)    0.98 (0.65--1.48)
  Q4 (≥7.4 mg/g)        47 135.7       130                275.8                                  1.33 (0.97--1.83)              1.37 (0.93--2.03)                                                1.33 (0.89--1.98)    1.25 (0.83--1.86)    1.25 (0.84--1.87)
  * P* for trend                                                                                 0.025                          0.019                                                            0.036                0.078                0.069
  CVD mortality                                                                                                                                                                                                                            
  Q1 (\<3.4 mg/g)       42 971.8       7                  16.3                                   1.00 (reference)               1.00 (reference)                                                 1.00 (reference)     1.00 (reference)     1.00 (reference)
  Q2 (3.4--4.7 mg/g)    47 491.7       11                 23.2                                   1.35 (0.52--3.51)              1.42 (0.34--6.00)                                                1.40 (0.33--5.90)    1.45 (0.34--6.15)    1.43 (0.94--6.05)
  Q3 (4.7--7.4 mg/g)    47 411.1       10                 21.1                                   1.09 (0.41--2.94)              1.97 (0.51--7.61)                                                1.93 (0.50--7.50)    2.05 (0.53--7.96)    2.03 (0.52--7.90)
  Q4 (≥7.4 mg/g)        47 135.7       22                 46.7                                   1.89 (0.77--4.61)              3.46 (0.97--12.35)                                               3.14 (0.86--11.48)   3.38 (0.92--12.39)   3.37 (0.92--12.36)
  * P* for trend                                                                                 0.163                          0.020                                                            0.038                0.029                0.028

SI units for ACR: divided by 8.84, mg/mmol. ACR indicates albumin/creatinine ratio; BMI, body mass index; CVD, cardiovascular disease; eGFR, estimated glomerular filtration rate; HDL, high‐density lipoprotein; HR, hazard ratio; LDL, low‐density lipoprotein; UACR, urine albumin:creatinine ratio.

Model 1: adjustment for age, sex, center, year of screening examination, smoking status, alcohol intake, regular exercise, education level; Model 2: Model 1 adjustments plus adjustment for BMI, hypertension, diabetes mellitus, and history of CVD; Model 3: Model 2 adjustments plus adjustment for eGFR; Model 4: Model 3 adjustments plus adjustment for HDL and LDL.

As can be seen for CVD mortality with each increasing quartile of UACR, there was an increase in the HR for CVD mortality relative to Quartile 1, HR=1; Quartile 2, HR=1.45; Quartile 3, HR=2.05; Quartile 4, HR=3.38, *P*‐value for the trend across increasing quartiles *P*=0.029.

Next we tested associations between baseline UACR and CVD mortality (Figure [1](#jah31750-fig-0001){ref-type="fig"}) and baseline UACR and all‐cause mortality (Figure [2](#jah31750-fig-0002){ref-type="fig"}) in clinically relevant subgroups. These analyses investigated trends across UACR quartiles and interaction between subgroup and UACR. For CVD mortality there were significant interactions with age and vigorous exercise. For all‐cause mortality no significant interactions with UACR were noted.

![Risk of CVD mortality according to subgroup and quartiles of ACR concentration. ACR indicates albumin/creatinine ratio; BMI, body mass index; CVD, cardiovascular disease; eGFR, estimated glomerular filtration rate; Homa, homeostatic model assessment; OR, odds ratio.](JAH3-5-e003245-g001){#jah31750-fig-0001}

![Risk of all‐cause mortality according to subgroup and quartiles of ACR concentration. ACR indicates albumin/creatinine ratio; BMI, body mass index; eGFR, estimated glomerular filtration rate; Homa, homeostatic model assessment; OR, odds ratio.](JAH3-5-e003245-g002){#jah31750-fig-0002}

We investigated associations between baseline UACR and both incident hypertension and incident diabetes mellitus at follow‐up. In the fully adjusted models there was a significant HR for the association between UACR and incident hypertension (highest UACR quartile HR 1.95 \[95% CI 1.51, 2.53\] and the *P*‐value for the trend across UACR quartiles was *P*\<0.001) (Table [4](#jah31750-tbl-0004){ref-type="table-wrap"}). In contrast, in the fully adjusted models there was a nonsignificant HR for the association between UACR and incident diabetes mellitus (highest UACR quartile HR 1.15 \[95% CI 0.79, 1.66\] and the *P*‐value for the trend across UACR quartiles was *P*=0.195) (Table [5](#jah31750-tbl-0005){ref-type="table-wrap"}).

###### 

Risk of Incident Hypertension According to Baseline ACR Quartiles

  ACR Quartiles, mg/g   Person‐Years   Number of Events   Incidence Rate (1000 Person‐Years)   Age‐Sex Adjusted HR (95% CI)   Multivariate HR[a](#jah31750-note-0010){ref-type="fn"}(95% CI)                                           
  --------------------- -------------- ------------------ ------------------------------------ ------------------------------ ---------------------------------------------------------------- ------------------- ------------------- -------------------
  N=9102                                                                                                                                                                                                                               
  Q1 (\<3.4 mg/g)       7171.4         167                23.3                                 1.00 (reference)               1.00 (reference)                                                 1.00 (reference)    1.00 (reference)    1.00 (reference)
  Q2 (3.4--4.7 mg/g)    7657.3         198                25.9                                 1.33 (1.08--1.64)              1.23 (0.93--1.63)                                                1.17 (0.88--1.55)   1.18 (0.89--1.56)   1.17 (0.89--1.56)
  Q3 (4.7--7.4 mg/g)    7655.3         241                31.5                                 1.72 (1.40--2.11)              1.61 (1.23--2.12)                                                1.46 (1.11--1.92)   1.48 (1.12--1.94)   1.50 (1.14--1.97)
  Q4 (≥7.4 mg/g)        7134.9         357                50.0                                 2.54 (2.10--3.08)              2.42 (1.88--3.13)                                                1.94 (1.50--2.50)   1.95 (1.51--2.53)   1.97 (1.52--2.55)
  * P* for trend                                                                               \<0.001                        \<0.001                                                          \<0.001             \<0.001             \<0.001

SI units for ACR: divided by 8.84, mg/mmol. ACR indicates albumin/creatinine ratio; BMI, body mass index; eGFR, estimated glomerular filtration rate; HDL, high‐density lipoprotein; HR, hazard ratio; LDL, low‐density lipoprotein; SBP, systolic blood pressure.

Model 1: adjustment for age, sex, center, year of screening examination, smoking status, alcohol intake, regular exercise, and education level; Model 2: Model 1 plus adjustment for SBP and BMI; Model 3: Model 2 plus adjustment for eGFR; Model 4: model 3 adjustments plus adjustment for HDL and LDL.

###### 

Risk of Incident Diabetes Mellitus According to Baseline ACR Quartiles

  ACR Quartiles, mg/g   Person‐Years   Number of Events   Incidence Rate (1000 Person‐Years)   Age‐Sex Adjusted HR (95% CI)   Multivariate HR[a](#jah31750-note-0012){ref-type="fn"}(95% CI)                                           
  --------------------- -------------- ------------------ ------------------------------------ ------------------------------ ---------------------------------------------------------------- ------------------- ------------------- -------------------
  N=10 930                                                                                                                                                                                                                             
  Q1 (\<3.4 mg/g)       9064.2         100                11.0                                 1.00 (reference)               1.00 (reference)                                                 1.00 (reference)    1.00 (reference)    1.00 (reference)
  Q2 (3.4--4.7 mg/g)    9754.9         106                10.9                                 1.07 (0.81--1.41)              1.01 (0.68--1.51)                                                0.83 (0.56--1.25)   0.83 (0.55--1.24)   0.84 (0.56--1.26)
  Q3 (4.7--7.4 mg/g)    9792.8         130                13.3                                 1.33 (1.02--1.74)              1.52 (1.05--2.20)                                                1.06 (0.73--1.55)   1.05 (0.72--1.53)   1.03 (0.71--1.51)
  Q4 (≥7.4 mg/g)        9337.3         175                18.7                                 1.70 (1.32--2.20)              1.83 (1.28--2.62)                                                1.16 (0.81--1.68)   1.15 (0.79--1.66)   1.14 (0.78--1.64)
  * P* for trend                                                                               \<0.001                        \<0.001                                                          0.174               0.195               0.240

SI units for ACR: divided by 8.84, mg/mmol. ACR indicates albumin/creatinine ratio; BMI, body mass index; eGFR, estimated glomerular filtration rate; HDL, high‐density lipoprotein; HR, hazard ratio; LDL, low‐density lipoprotein.

Model 1: adjustment for age, sex, center, year of screening examination, smoking status, alcohol intake, regular exercise, education level; Model 2: Model 1 plus adjustment for glucose, family history of diabetes mellitus and BMI; Model 3: Model 2 plus adjustment for eGFR; Model 4: Model 3 adjustments plus adjustment for HDL and LDL.

Discussion {#jah31750-sec-0011}
==========

We show for the first time that UACR below 30 mg/g is associated with increased risk of incident hypertension and CVD mortality over 10 years of follow‐up. Our results show there was a linear trend for increased risk of incident hypertension and CVD mortality, with very low‐grade albuminuria defined by UACR, and these trends were independent of eGFR levels. eGFR only varied by 0.4 mL/min across UACR quartiles, and the HRs for the associations between UACR and each outcome were not materially affected by adjustment for eGFR in the regression models. The associations we observed are in a healthy, young occupational cohort without overt renal disease and although many of the risk factors for type 2 diabetes mellitus and hypertension are shared, it is important to note that there was no significant association between baseline UACR and incident diabetes mellitus. Importantly, our data add uniquely to current knowledge, since we show that very low levels of albuminuria are a risk factor for both incident hypertension and also CVD mortality and the linear increase in risk from 0 to \<30 mg/g therefore suggests strongly that any albuminuria is a risk factor for vascular disease. Whether hypertension represents the intermediary causal link between UACR and increased CVD mortality is uncertain, as it is not possible to prove a causal link from this cohort study.

In general, urinary albumin excretion is classified as normoalbuminuria (\<30 mg/day or UACR \<30 mg/g), microalbuminuria (30--300 mg/day or UACR 30--300 mg/g), and macroalbuminuria (\>300 mg/day or UACR \>300 mg/g). Thus, it is important to note that all individuals included in this study in all quartiles of UACR would be classified has having normoalbuminuria. Consequently, our results strongly suggest that even within the normal range of urinary albumin excretion, an increase in UACR is associated with CVD mortality and increased risk of developing incident hypertension during follow‐up.

Low levels of eGFR are associated with renal impairment and albuminuria, but our results show clearly that the association between low‐grade albuminuria and mortality outcomes and incident hypertension were independent of eGFR levels. A previous cohort study undertaken in North and South America and Europe that followed individuals aged ≥55 years for a median 4.5 years showed that any degree of albuminuria was a risk factor for CV events.[11](#jah31750-bib-0011){ref-type="ref"} Another multicenter cohort study involving patients with hypertension and left ventricular hypertrophy also showed an association between UACR and increased cardiovascular morbidity and mortality with no threshold of UACR contributing to increased risk.[12](#jah31750-bib-0012){ref-type="ref"} These results are in keeping with our results and with our previous study in which we showed an association between different cardiovascular risk factors and low‐grade albuminuria.[13](#jah31750-bib-0013){ref-type="ref"} However, the baseline characteristics of subjects in these studies were very different from the baseline characteristics of subjects in the present study. In these previous studies, there was inclusion of subjects with recognized cardiovascular risk factors at baseline, such as diabetes,[11](#jah31750-bib-0011){ref-type="ref"} hypertension with left ventricular hypertrophy,[12](#jah31750-bib-0012){ref-type="ref"} and coronary artery disease.[13](#jah31750-bib-0013){ref-type="ref"} Furthermore, baseline UACR was notably higher in these previous studies than in the presented data. Consequently, the presented data are novel and this is the first study to show that UACR below 30 mg/g is associated with increased risk of CVD mortality.

Why is low‐grade albuminuria, UACR below 30 mg/g, associated with increased CVD mortality and incident hypertension? Increased albumin excretion is the net result of glomerular filtration and tubular resorption, and it is suggested that in normal physiological conditions there is little filtration. When irreversible increases in albumin excretion occur it is assumed that there is increased glomerular hydraulic pressure, increased glomerular filtration coefficient, and change in size and charge selectivity of the glomerular membrane.[7](#jah31750-bib-0007){ref-type="ref"} The mechanisms linking increased albuminuria and cardiovascular mortality are uncertain, but it is likely that increased urinary albumin excretion reflects widespread vascular endothelial cell dysfunction,[5](#jah31750-bib-0005){ref-type="ref"}, [14](#jah31750-bib-0014){ref-type="ref"} and it is plausible that this might predispose to increased accumulation of atherogenic lipoproteins within the subendothelial cell space.[15](#jah31750-bib-0015){ref-type="ref"} Thus, increased albuminuria might reflect glomerular and/or systemic vascular endothelial dysfunction that precedes development of hypertension in humans.[16](#jah31750-bib-0016){ref-type="ref"} In previous cross‐sectional studies, increased urinary albumin excretion was associated with increased blood pressure in subjects with hypertension[17](#jah31750-bib-0017){ref-type="ref"}, [18](#jah31750-bib-0018){ref-type="ref"} and in the general population,[19](#jah31750-bib-0019){ref-type="ref"} suggesting that the increased level of urinary albumin excretion in the present study could be in part due to an increase in blood pressure below levels to diagnose hypertension.

Although CVD and diabetes mellitus share many risk factors in common (the "common soil" hypothesis[8](#jah31750-bib-0008){ref-type="ref"}) and as discussed above microalbuminuria occurs in people with diabetes mellitus and CVD, our data suggest a disconnect between diabetes and CVD, since in contrast to CVD mortality and hypertension, low‐grade albuminuria was not significantly associated with any marked increase in incident diabetes mellitus. Thus, we suggest that these data lend credence to the notion that microalbuminuria/albuminuria occurs as a consequence of vascular dysfunction in diabetes mellitus, rather than albuminuria/vascular dysfunction being a causal factor in the pathogenesis of diabetes mellitus.

Our study does have some limitations that should be discussed. UACR measurement was only available from a single measurement and since UACR can vary from day to day, this will result in imprecision in the UACR measurement. Moreover, although the absolute variability in ACR decreases with the magnitude of albuminuria, on the other hand a percentage of baseline ACR variability increases.[20](#jah31750-bib-0020){ref-type="ref"} However, there is a considerable amount of evidence showing that a simple single‐voided test is reliable and useful in screening for disease and follow‐up of patients, and this methodology avoids the problems associated with a 24‐hour urine collection.[20](#jah31750-bib-0020){ref-type="ref"}, [21](#jah31750-bib-0021){ref-type="ref"}, [22](#jah31750-bib-0022){ref-type="ref"}, [23](#jah31750-bib-0023){ref-type="ref"}, [24](#jah31750-bib-0024){ref-type="ref"} Despite the potential imprecision associated with a single voided measurement of UACR, we have studied a large number of subjects in this cohort and any imprecision in the measurement of UACR would bias results towards the null. Although our subjects predominantly have normal renal function, it is possible that eGFR values are underestimated since it is known that the MDRD Study equation underestimates measured GFR when GFR is ≥60 mL/min per 1.73 m^2^ in healthy individuals.[25](#jah31750-bib-0025){ref-type="ref"} Furthermore, it is possible that development of diabetes mellitus or hypertension during follow‐up has influenced our results, although our study design has limited this possibility by exclusion of these subjects at baseline. Although the follow‐up time was a little different for studying the associations between baseline UACR and incident diabetes mellitus and incident hypertension, compared to studying associations with mortality outcomes, it should be noted that there were similar associations between baseline UACR and incident hypertension and CVD mortality, in contrast to the (lack of an) association between baseline UACR and incident diabetes mellitus. Thus, it seems unlikely that the shorter period of follow‐up for incident diabetes mellitus has influenced our results.

In summary, our results show for the first time that in a young predominantly healthy occupational cohort, UACR below 30 mg/g is an independent risk factor for incident hypertension and CVD mortality during a maximum of 11 years of follow‐up. In contrast, low‐grade albuminuria was not a risk factor for incident diabetes during the same period of follow‐up. Whether hypertension represents the intermediary causal link between UACR and increased CVD mortality is uncertain, as it is not possible to prove a causal link from this cohort study.
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